Effectiveness of Tralokinumab for Different Anatomical Sites and Clinical Signs in Atopic Dermatitis: A 36-Week Real-World Study

An anti-interleukin-13 antibody tralokinumab is effective for atopic dermatitis (AD), but its effectiveness on different anatomical sites and clinical signs remains unclear. To assess the effectiveness of tralokinumab on different anatomical sites and clinical signs of AD. This study included 129 moderate-to-severe AD patients treated with tralokinumab for 36 weeks. Eczema Area and Severity Index (EASI) scores were analyzed on four anatomical sites (head/neck, trunk, upper, and lower limbs) and four clinical signs (erythema, edema/papulation, excoriation, and lichenification) at weeks 0, 4, 12, 24, and 36. Tralokinumab consistently reduced EASI scores on 4 anatomical sites and 4 clinical signs. The magnitude of decreasing EASI appeared highest on lower limbs　while the achievement rates of EASI 75 at week 36 on 4 anatomical sites were mostly similar (72.6-77.6%). The magnitude of decreasing EASI and achieving EASI 75 or 100 appeared highest for excoriation, and the rates of EASI 75 at week 36 for erythema, excoriation, lichenification and edema/papulation were 71.1%, 69.4%, 68.4%, and 60.5%, respectively. Tralokinumab reduced EASI scores across various anatomical sites and clinical signs in moderate-to-severe AD patients. These findings suggest that tralokinumab may be widely useful for diverse skin manifestations of AD.